Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents

被引：17

作者：

Sahebi, Firoozeh ^{[1
]}

Iacobelli, Simona ^{[2
]}

Sbianchi, Giulia ^{[2
]}

Koster, Linda ^{[3
]}

Blaise, Didier ^{[4
]}

Remenyi, Peter ^{[5
]}

Russell, Nigel H. ^{[6
]}

Ljungman, Per ^{[7
]}

Kobbe, Guido ^{[8
]}

Apperley, Jane ^{[9
]}

Trneny, Marek ^{[10
]}

Krejci, Marta ^{[11
]}

Wiktor-Jedrzejczak, Wieslaw ^{[12
]}

Sanchez, James F. ^{[1
]}

Schaap, Nicolaas ^{[13
]}

Isaksson, Cecilia ^{[14
]}

Lenhoff, Stig ^{[15
]}

Browne, Paul ^{[16
]}

Scheid, Christof ^{[17
]}

Wilson, Keith M. O. ^{[18
]}

Yakoub-Agha, Ibrahim ^{[19
]}

Muniz, Soledad Gonzalez ^{[20
]}

Schoenland, Stefan ^{[21
]}

Morris, Curly ^{[22
]}

Garderet, Laurent ^{[23
]}

Kroeger, Nicolaus ^{[24
]}

机构：

[1] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, 1500 Duarte Rd, Duarte, CA 91010 USA

[2] Univ Roma Tor Vergata, Dept Biol, Rome, Italy

[3] EBMT Data Off Leiden, Leiden, Netherlands

[4] Ctr Rech Cancerol Marseille, Inst Paoli Calmettes, Dept Hematol, Marseille, France

[5] St Istvan & St Laszlo Hosp, Budapest, Hungary

[6] Nottingham Univ Hosp, Dept Haematol, Nottingham, England

[7] Karolinska Univ Hosp, Div Hematol, Dept Med, Stockholm, Sweden

[8] Heinrich Heine Univ, Dept Hematol Oncol & Clin Immunol, Dusseldorf, Germany

[9] Imperial Coll, Hammersmith Hosp, Dept Haematol, London, England

[10] Charles Univ Hosp, Dept Hematol, Prague, Czech Republic

[11] Univ Hosp Brno, Dept Internal Med Hematol & Oncol, Brno, Czech Republic

[12] Cent Clin Hosp, Dept Hematol Oncol & Internal Med, Warsaw, Poland

[13] Radboud Univ Nijmegen, Med Ctr, Dept Hematol, Nijmegen, Netherlands

[14] Umea Univ Hosp, Dept Hematol, Umea, Sweden

[15] Skane Univ Hosp, Dept Hematol, Lund, Sweden

[16] St James Hosp, Dept Haematol, Dublin, Ireland

[17] Univ Cologne, Dept Internal Med 1, Cologne, Germany

[18] Univ Hosp Wales, Dept Haematol, Cardiff, S Glam, Wales

[19] CHRU Lille, Dept Hematol, Lille, France

[20] Hosp Univ Cent Asturias, Dept Hematol, Oviedo, Spain

[21] Heidelberg Univ, Dept Internal Med 5, Heidelberg, Germany

[22] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland

[23] Hosp St Antoine, Dept Hematol & Cellular Therapy, Paris, France

[24] Univ Hosp Eppendorf, Dept Stem Cell Transplantat, Hamburg, Germany

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2018年 / 24卷 / 05期

关键词：

Multiple myeloma; Second primary malignancies; Immunomodulatory drugs; Proteasome inhibitors; Plerixafor; STEM-CELL TRANSPLANTATION; LENALIDOMIDE MAINTENANCE; MYELODYSPLASTIC SYNDROME; THERAPY; SECONDARY; NEOPLASMS; LEUKEMIA; RISK;

D O I：

10.1016/j.bbmt.2018.01.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The advent of novel agents for multiple myeloma (MM) is cause for a re-examination of the incidence of second primary malignancies (SPM5). We examined the SPM rate in MM patients who were enrolled in the prospective observational CALM (Collaboration to Collect Autologous Transplant outcome in Lymphoma and Myeloma) study. Between 2008 and 2012, 3204 patients with MM underwent a first autologous hematopoietic stem cell transplantation. Plerixafor was used as a mobilizing agent for patients with poor (or potentially poor) stem cell mobilization as defined by the respective centers. A total of 135 patients developed SPM5, with a cumulative incidence of 5.3% (95% confidence interval, 4.4 to 6.3) at 72 months. Ninety-four patients developed solid tumors, 30 developed hematologic malignancies, and 11 developed an SPM of an unknown type. The cumulative incidence of known hematologic and solid malignancies were 1.4% and 3.6%, respectively, at 72 months. In a univariate analysis, use of radiotherapy, type of induction regimen, hematopoietic stem cell dose, poor mobilizer status, plerixafor use, and sex did not influence the cumulative incidence of SPMs. Only age over 65 years was statistically associated with an increased incidence. Overall, the incidence of SPMs was comparable to earlier estimations of SPMs in MM. (C) 2018 American Society for Blood and Marrow Transplantation.

引用

页码：930 / 936

页数：7

共 25 条

[21] Myeloid Neoplasms Secondary to Plasma Cell Myeloma: An Intrinsic Predisposition or Therapy-Related Phenomenon? A Clinicopathologic Study of 41 Cases and Correlation of Cytogenetic Features With Treatment Regimens [J].

Reddi, Deepti M. ;

Lu, Chuanyi M. ;

Fedoriw, George ;

Liu, Yen-Chun ;

Wang, Frances F. ;

Ely, Scott ;

Boswell, Elizabeth L. ;

Louissaint, Abner, Jr. ;

Arcasoy, Murat O. ;

Goodman, Barbara K. ;

Wang, Endi .

AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2012, 138 (06) :855-866

[22] Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide [J].

Rifkin, Robert M. ;

Abonour, Rafat ;

Shah, Jatin J. ;

Mehta, Jayesh ;

Narang, Mohit ;

Terebelo, Howard ;

Gasparetto, Cristina ;

Toomey, Kathleen ;

Hardin, James W. ;

Lu, Jane Jie ;

Kenvin, Laurie ;

Srinivasan, Shankar ;

Knight, Robert ;

Nagarwala, Yasir ;

Durie, Brian G. M. .

LEUKEMIA & LYMPHOMA, 2016, 57 (09) :2228-2231

[23] Second malignancies after multiple myeloma: from 1960s to 2010s [J].

Thomas, Anish ;

Mailankody, Sham ;

Korde, Neha ;

Kristinsson, Sigurdur Y. ;

Turesson, Ingemar ;

Landgren, Ola .

BLOOD, 2012, 119 (12) :2731-2737

[24] Time Trend of Multiple Myeloma and Associated Secondary Primary Malignancies in Asian Patients: A Taiwan Population-Based Study [J].

Tzeng, Huey-En ;

Lin, Cheng-Li ;

Tsai, Chun-Hao ;

Tang, Chih-Hsin ;

Hwang, Wen-Li ;

Cheng, Ya-Wen ;

Sung, Fung-Chang ;

Chung, Chi-Jung .

PLOS ONE, 2013, 8 (07)

[25] The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study [J].

Youlden, Danny R. ;

Baade, Peter D. .

BMC CANCER, 2011, 11

← 1 2 3 →